{"prompt": "['Date: June 30, 2020', 'Version: 8.0', 'Page: 29 of 52', 'rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare', 'fatalities have occurred. The risk of myopathy is increased by high levels of HMG-CoA reductase', 'inhibitory activity in plasma. SYN-010 is designed to limit systemic exposure of HMG-CoA', 'reductase inhibiting lovastatin species and no myopathy or rhabdomyolysis were observed in', 'Phase 1 or Phase 2a clinical trials with up to 12 weeks of SYN-010 42 mg dosing. Transient and', 'reversible increases in serum CK were observed in two subjects treated with SYN-010 42 mg for', '8 weeks in the Phase 2a clinical trial; however, these were deemed unrelated to study drug by', 'the investigator and returned to normal without discontinuation of SYN-010.', 'Clinical studies with the commercially-available cholesterol-lowering lovastatin formulation', 'Mevacor\u00ae (Merck) also found persistent increases (to more than 3 times the upper limit of', 'normal) in serum transaminases occurred in 1.9% of adult patients who received lovastatin for', 'at least one year in early clinical trials. When the drug was interrupted or discontinued in these', 'patients, the transaminase levels usually fell slowly to pretreatment levels. The increases usually', 'appeared 3 to 12 months after the start of therapy with lovastatin and were not associated with', 'jaundice or other clinical signs or symptoms. SYN-010 is designed to limit systemic exposure', 'to lovastatin species and SYN-010 21 mg and 42 mg doses did not cause clinically meaningful or', 'persistent alterations to serum transaminase levels in Phase 1 or Phase 2a clinical trials.', '8.4.1.2 Dose handling', 'All study drug has been manufactured according to Good Manufacturing Practice for Medicinal', 'Products and the relevant regulatory requirements. The study drug will be distributed by PCI', 'Pharma Services. All packaging and labeling operations have been performed according', 'to Good Manufacturing Practice for Medicinal Products and the relevant regulatory', 'requirements.', 'Study drug at the clinical study sites should be stored at controlled room temperature in a', 'locked area accessible only to appropriate study personnel. Study drug bottles, and any unused', 'study drug, will be retained by the study site until final reconciliation is completed, then', 'destroyed by the study site according to local procedures. The investigator must provide an', 'explanation for any missing bottles or missing capsules. Any missing bottles or capsules must be', 'documented in the applicable source documentation and Accountability Log.', '8.4.1.3 Dose calculation', 'SYN-010 doses were selected based on previous clinical experience in Phase 1 and Phase 2a', 'clinical studies. These studies showed that SYN-010 provided continuous delivery of lovastatin', 'lactone throughout the colon, and stool concentrations for the SYN-010 21 mg and 42 mg doses', 'were equivalent to concentrations that inhibited methane production by ~60% and ~90%', 'respectively in stool samples from an IBS-C patient in vitro. Moreover, these SYN-010 doses did', 'not cause significant or persistent systemic effects on blood chemistry, hematology or', 'urinalysis parameters over 12 weeks of dosing in Phase 2a clinical trials.', '8.4.1.4 Dose administration']['Date: June 30, 2020', 'Version: 8.0', 'Page: 30 of 52', 'The study drugs, SYN-010 21 mg or 42 mg (active) or placebo (control), will be administered', 'orally once daily at bedtime for 12 weeks.', '8.4.1.5 Dose modification', 'No dose adjustments will be allowed.', '8.5', 'Blinding', 'In compliance with applicable regulations, in the event of a SUSAR completed for patients on', \"investigational drug SYN-010, the patient's treatment code will be unblinded and reported to the\", 'health authorities. SUSARs involving placebo would not be required to be submitted to the health', 'authorities, however local and institutional regulations should be followed. Any safety reports', 'completed, do not need to be unblinded before submitting to other investigators. Submission of', 'safety reports to the ethics committee should follow local reporting regulations.', '8.5.1 Emergency unblinding by the investigator', 'Unblinding may occur for emergency purposes only. The investigator should note that the', 'occurrence of a serious adverse event or progressive disease should not routinely precipitate the', 'immediate unblinding of the label. If unblinding is necessary for the treatment of a patient for a', 'serious adverse event, every attempt should be made to contact the investigator prior to', 'unblinding. If this is not feasible, then the investigator must be contacted within 24 hours of', 'unblinding.', '8.6', 'Drug logistics and accountability', 'All study drugs will be stored at the investigational site in accordance with Good Clinical Practice', '(GCP) and Good Manufacturing Practices (GMP) requirements and the instructions given by the', 'clinical supplies department of the Institution and will be inaccessible to unauthorized personnel.', '8.6.1', 'Storage', 'All investigational product will be kept in a locked area with access limited to study staff only. The', 'locked area will be maintained under controlled temperature conditions at 20\u00b0C-25\u00b0C (68\u00b0F-77\u00b0F),', 'and away from light and moisture.', '8.6.2 Accountability', 'The investigator, or a responsible party designated by the investigator, must maintain a careful', 'record of the inventory and disposition of the agent(s) (investigational or free of charge) using the', 'Drug Accountability Record or another comparable drug accountability form.', '8.6.3', 'Destruction and return', 'At the end of the study, unused supplies of SYN-010 and other investigational agents should be', 'destroyed appropriately and according to institutional policies. Destruction will be documented in', 'the Drug Accountability Record Form.']\n\n###\n\n", "completion": "END"}